Elsevier

The Lancet

Volume 372, Issue 9635, 26 July–1 August 2008, Pages 266-267
The Lancet

Comment
Life and death in the cART era

https://doi.org/10.1016/S0140-6736(08)61086-7Get rights and content

References (5)

  • Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis

    Lancet

    (2000)
  • Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

    Lancet

    (2008)
There are more references available in the full text version of this article.

Cited by (27)

  • How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation

    2017, Blood
    Citation Excerpt :

    In pre-alloHCT counseling, the unlikelihood of a virological cure of HIV infection should be carefully discussed with patients. Despite the example of the “Berlin patient,” HIV remains an incurable source of significant morbidity and mortality for infected patients.11,70-72 The challenges of eliminating HIV are several-fold and include the need to eradicate the viral reservoir while protecting the patient from future infection/reinfection by providing them with immunological resistance to HIV.

  • CTLA-4<sup>+</sup>PD-1<sup>−</sup> Memory CD4<sup>+</sup> T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques

    2017, Immunity
    Citation Excerpt :

    The ability of antiretroviral therapy (ART) to effectively suppress HIV-1 replication has dramatically reduced HIV morbidity and mortality (Bhaskaran et al., 2008; Cooper, 2008).

View all citing articles on Scopus
View full text